Bulk Manufacturer of Controlled Substances Application: Organix Chemistry Solutions LLC, 66747-66748 [2022-24103]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 213 / Friday, November 4, 2022 / Notices
ACTION:
Notice.
Notice is hereby given that
the U.S. International Trade
Commission has issued a limited
exclusion order (‘‘LEO’’) against
infringing products manufactured and/
or imported by or on behalf of Proton
Sports Inc. (‘‘Proton’’) of Scottsdale,
Arizona, and a cease and desist order
(‘‘CDO’’) against Proton. The
investigation is terminated.
FOR FURTHER INFORMATION CONTACT:
Clint Gerdine, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
708–2310. Copies of non-confidential
documents filed in connection with this
investigation may be viewed on the
Commission’s electronic docket system
(‘‘EDIS’’) at https://edis.usitc.gov. For
help accessing EDIS, please email
EDIS3Help@usitc.gov. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
Hearing-impaired persons are advised
that information on this matter can be
obtained by contacting the
Commission’s TDD terminal, telephone
(202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on November 2, 2021, based on a
complaint filed and supplemented by
Easton Diamond Sports, LLC (‘‘Easton’’)
of Thousand Oaks, California. 86 FR
60468–469 (Nov. 2, 2021). The
complaint alleges a violation of section
337 of the Tariff Act, as amended, 19
U.S.C. 1337, based on the importation,
sale for importation, or sale in the
United States after importation of
certain composite baseball and softball
bats and components thereof by reason
of infringement of one or more asserted
claims of U.S. Patent No. 6,997,826
(‘‘the ’826 patent’’). Id. The complaint
further alleges the existence of a
domestic industry. Id. The
Commission’s notice of investigation
(‘‘NOI’’) names Proton; Juno Athletics
LLC (‘‘Juno’’) of Aventura, Florida; and
Monsta Athletics LLC (‘‘Monsta’’) of
Calimesa, California as respondents. Id.
at 60469. The Office of Unfair Import
Investigations is not a party to this
investigation. Id.
On January 25, 2022, the Commission
amended the complaint and NOI to add
TianChang Zhengmu Aluminum
Technology Co., Ltd. (‘‘TZA’’) of
Tianching City, China as a respondent.
See Order No. 8 (Dec. 28, 2021),
unreviewed by Comm’n Notice (Jan. 25,
2022). On February 16, 2022, the
Commission terminated TZA from the
investigation based on withdrawal of
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:12 Nov 03, 2022
Jkt 259001
the complaint. See Order No. 11 (Jan.
28, 2022), unreviewed by Comm’n
Notice (Feb. 16, 2022).
On April 12, 2022, the Commission
found Proton in default for failure to
respond to the complaint and NOI and
for failure to respond to these order to
show cause why it should not be found
in default for failing to respond to the
complaint and NOI (Order No. 7). See
Order No. 13 (March 30, 2022),
unreviewed by Comm’n Notice (April
12, 2022).
On July 25, 2022, the Commission
terminated respondent Monsta from the
investigation based on withdrawal of
the complaint. See Order No. 21 (June
27, 2022), unreviewed by Comm’n
Notice (July 25, 2022).
On July 11, 2022, the currently
presiding ALJ issued Order No. 23,
which terminated the investigation as to
the last participating respondent, Juno,
based on a settlement agreement. Easton
did not request issuance of a general
exclusion order. The Commission
determined not to review Order No. 23
and requested written submissions on
the issues of remedy, the public interest,
and bonding with respect to Proton. 87
FR 48690–91 (Aug. 10, 2022).
On August 26, 2022, Easton submitted
briefing responsive to the Commission’s
request. Easton argued that the
Commission should issue an LEO
directed to Proton’s infringing products
and a CDO directed to Proton. No other
submissions were received.
When the conditions in section
337(g)(1)(A)–(E) (19 U.S.C.
1337(g)(1)(A)–(E)) have been satisfied,
section 337(g)(1) and Commission Rule
210.16(c) (19 CFR 210.16(c)) direct the
Commission, upon request, to issue a
limited exclusion order or a cease and
desist order or both against a respondent
found in default, based on the
allegations regarding a violation of
section 337 in the Complaint, which are
presumed to be true, unless after
consideration of the public interest
factors in section 337(g)(1), it finds that
such relief should not issue.
Having reviewed the record in the
investigation, including written
submissions from Easton, the
Commission has determined pursuant to
section 337(g)(1) that the appropriate
remedy in this investigation is an LEO
directed to the defaulting respondent
prohibiting the unlicensed entry of
composite baseball and softball bats and
components thereof that infringe one or
more of claims 1–5, 9–12, 14–15, and
18–19 of the ’826 patent, and that are
manufactured abroad by or on behalf of,
or imported by or on behalf of Proton,
or any of its affiliated companies,
parents, subsidiaries, or other related
PO 00000
Frm 00109
Fmt 4703
Sfmt 4703
66747
business entities, or their successors or
assigns.
The Commission has also determined
to issue a CDO prohibiting Proton from
conducting any of the following
activities in the United States:
importing, selling, marketing,
advertising, distributing, offering for
sale, transferring (except for
exportation), and soliciting U.S. agents
or distributors for composite baseball
and softball bats and components
thereof that infringe one or more of
claims 1–5, 9–12, 14–15, and 18–19 of
the ’826 patent.
The Commission has further
determined that the public interest
factors enumerated in section 337(g)(1)
do not preclude issuance of the LEO or
CDO. Finally, the Commission has
determined that a bond in the amount
of 100 percent of the entered value of
the covered products is required during
the period of Presidential review (19
U.S.C. 1337(j)). The Commission’s order
was delivered to the President and to
the United States Trade Representative
on the day of its issuance.
The Commission voted to approve
this determination on November 1,
2022.
The authority for the Commission’s
determinations is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: November 1, 2022.
Katherine Hiner,
Acting Secretary to the Commission.
[FR Doc. 2022–24053 Filed 11–3–22; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1099]
Bulk Manufacturer of Controlled
Substances Application: Organix
Chemistry Solutions LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Organix Chemistry Solutions
LLC, has applied to be registered as a
bulk manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
SUMMARY:
E:\FR\FM\04NON1.SGM
04NON1
66748
Federal Register / Vol. 87, No. 213 / Friday, November 4, 2022 / Notices
electronic comments on or objections to
the issuance of the proposed registration
on or before January 3, 2023. Such
persons may also file a written request
for a hearing on the application on or
before January 3, 2023.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
In
accordance with 21 CFR 1301.33(a), this
is notice that on September 26, 2022,
Organix Chemistry Solutions LLC, 240
Salem Street, Woburn, Massachusetts
01801–2029, applied to be registered as
a bulk manufacturer of the following
basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
Gamma Hydroxybutyric Acid ...........................................................................................................................................
Lysergic acid diethylamide ..............................................................................................................................................
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
Mescaline .........................................................................................................................................................................
3,4,5- Trimethoxyamphetamine .......................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine ..........................................................................................................................
3,4-Methylenedioxyamphetamine ....................................................................................................................................
3,4-Methylenedioxymethamphetamine ............................................................................................................................
5-Methoxy-N–N-dimethyltryptamine ................................................................................................................................
Alpha-Methyltryptamine ...................................................................................................................................................
Bufotenine ........................................................................................................................................................................
Diethyltryptamine .............................................................................................................................................................
Dimethyltryptamine ..........................................................................................................................................................
Psilocybin .........................................................................................................................................................................
Psilocyn ...........................................................................................................................................................................
2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C–D) ..................................................................................................
2-(2,5-Dimethoxyphenyl) ethanamine (2C–H) .................................................................................................................
2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C–I) .......................................................................................................
Heroin ..............................................................................................................................................................................
Morphine ..........................................................................................................................................................................
The company plans to synthesize the
above listed controlled substances for
distribution to its customers. In
reference to dug codes 7360
(Marihuana), and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
drug codes are authorized for this
registration.
Kristi O’Malley,
Assistant Administrator.
[FR Doc. 2022–24103 Filed 11–3–22; 8:45 am]
BILLING CODE P
DEPARTMENT OF LABOR
khammond on DSKJM1Z7X2PROD with NOTICES
Employee Benefits Security
Administration
214th Meeting of the Advisory Council
on Employee Welfare and Pension
Benefit Plans; Notice of Meeting
Pursuant to the authority contained in
Section 512 of the Employee Retirement
Income Security Act of 1974 (ERISA), 29
U.S.C. 1142, the 214th open meeting of
the Advisory Council on Employee
Welfare and Pension Benefit Plans (also
VerDate Sep<11>2014
18:12 Nov 03, 2022
Jkt 259001
known as the ERISA Advisory Council)
will be held on December 8–9, 2022.
On Thursday, December 8, 2022, the
meeting will begin at 1 p.m. and end at
approximately 4:30 p.m. (ET). On
Friday, December 9, 2022, the meeting
will begin at 8:30 a.m. and end at
approximately 3 p.m. (ET), with a onehour break for lunch. The meeting will
take place at the U.S. Department of
Labor, 200 Constitution Avenue NW,
Room C5515—1A/1B, Washington, DC
20210. The meeting will also be
accessible via teleconference and some
participants, as well as members of the
public, may elect to attend virtually.
Instructions for public teleconference
access will be available on the ERISA
Advisory Council’s web page at https://
www.dol.gov/agencies/ebsa/about-ebsa/
about-us/erisa-advisory-council
approximately one week prior to the
meeting.
The purpose of the open meeting is
for the members of the ERISA Advisory
Council to finalize their observations
and recommendations on the issues
they studied in 2022, present their
observations and recommendations to
the Department of Labor, and receive an
update from leadership of the Employee
PO 00000
Frm 00110
Fmt 4703
Sfmt 4703
2010
7315
7360
7370
7381
7390
7392
7400
7405
7431
7432
7433
7434
7435
7437
7438
7508
7517
7518
9200
9300
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
Benefits Security Administration
(EBSA).
The issues studied by the ERISA
Advisory Council in 2022 are: (1)
Cybersecurity Issues Affecting Health
Benefit Plans, and (2) Cybersecurity
Insurance and Employee Benefit Plans.
Descriptions of these issues are
available on the ERISA Advisory
Council’s web page at https://
www.dol.gov/agencies/ebsa/about-ebsa/
about-us/erisa-advisory-council.
Organizations or members of the
public wishing to submit a written
statement may do so on or before
Thursday, December 1, 2022, to
Christine Donahue, Executive Secretary,
ERISA Advisory Council. Statements
should be transmitted electronically as
an email attachment in text or pdf
format to donahue.christine@dol.gov.
Statements transmitted electronically
that are included in the body of the
email will not be accepted. Relevant
statements received on or before
Thursday, December 1, 2022, will be
included in the record of the meeting
and made available through the EBSA
Public Disclosure Room. No deletions,
modifications, or redactions will be
made to the statements received as they
are public records.
E:\FR\FM\04NON1.SGM
04NON1
]]>Agencies
[Federal Register Volume 87, Number 213 (Friday, November 4, 2022)]
[Notices]
[Pages 66747-66748]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-24103]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1099]
Bulk Manufacturer of Controlled Substances Application: Organix
Chemistry Solutions LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Organix Chemistry Solutions LLC, has applied to be registered
as a bulk manufacturer of basic class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION listed below for further drug
information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit
[[Page 66748]]
electronic comments on or objections to the issuance of the proposed
registration on or before January 3, 2023. Such persons may also file a
written request for a hearing on the application on or before January
3, 2023.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on September 26, 2022, Organix Chemistry Solutions LLC,
240 Salem Street, Woburn, Massachusetts 01801-2029, applied to be
registered as a bulk manufacturer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid................ 2010 I
Lysergic acid diethylamide............... 7315 I
Marihuana................................ 7360 I
Tetrahydrocannabinols.................... 7370 I
Mescaline................................ 7381 I
3,4,5- Trimethoxyamphetamine............. 7390 I
4-Bromo-2,5-dimethoxyphenethylamine...... 7392 I
3,4-Methylenedioxyamphetamine............ 7400 I
3,4-Methylenedioxymethamphetamine........ 7405 I
5-Methoxy-N-N-dimethyltryptamine......... 7431 I
Alpha-Methyltryptamine................... 7432 I
Bufotenine............................... 7433 I
Diethyltryptamine........................ 7434 I
Dimethyltryptamine....................... 7435 I
Psilocybin............................... 7437 I
Psilocyn................................. 7438 I
2-(2,5-Dimethoxy-4-methylphenyl) 7508 I
ethanamine (2C-D).
2-(2,5-Dimethoxyphenyl) ethanamine (2C-H) 7517 I
2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine 7518 I
(2C-I).
Heroin................................... 9200 I
Morphine................................. 9300 II
------------------------------------------------------------------------
The company plans to synthesize the above listed controlled
substances for distribution to its customers. In reference to dug codes
7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans
to bulk manufacture these drugs as synthetic. No other activities for
these drug codes are authorized for this registration.
Kristi O'Malley,
Assistant Administrator.
[FR Doc. 2022-24103 Filed 11-3-22; 8:45 am]
BILLING CODE P
